Hospital Research Teams

The Liang Deng Lab

Share
Back to top

Research

Liang Deng, MD, PhD
Liang Deng, MD, PhD

Our laboratory is focused on understanding how poxviruses are detected by the host innate immune sensing mechanisms and how poxviruses evade host antiviral responses. We are also interested in the development of poxvirus-based oncolytic and immunotherapy for cancers including melanoma.

View Lab Overview

Research Projects

Figure 1
The Liang Deng Lab

Featured News

Pictured: Liang Deng
At Work: Physician-Scientist Liang Deng
Physician-scientist Liang Deng cares for patients with melanoma and other skin cancers, and also conducts innovative research on poxviruses.
Imagination to Discovery
Three emerging investigators are tackling the mysteries of biology and cancer at Memorial Sloan Kettering.

Publications

Yang, N., Wang, Y., Dai, P., Li, T., Zierhut, C., Tan, A., Zhang, Z., Pan, H., Li, Z., Ordureau, A., Xiang, J.Z., Hendrickson, R.C., Funabiki H., Chen, Z., Deng, L. (2023) Vaccinia E5 is a major inhibitor of the DNA sensor cGAS. Nat Commun, 14(1):2898. doi: 10.1038/s41467-023-38514-5 (PMC10201048).

Yang, N., #, Wang, Y.,#, Liu, S., Tariq, S.B., Luna, J. M., Mazo G., Tan, A., Zhang, T., Wang, J., Yan, W.,  Choi, J., Rossi, A., Xiang, J.Z., Rice, C. M., Merghoub, T., Wolchok, J. D., and Deng, L. (2023) OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs. Journal Experimental Medicine 220(8):e20221166. Epub 2023 May 5. PMID: 37145142.

Gu, L., Lin, E., Liu, S., Yang, N., Kurtansky, N., Neumann, N., Stoll, J., Lezcano, C., Pulitzer, M., Noor, S., Markova, A., Rossi, A., Dickson, M., and Deng L.  (2023) Efficacy of Immunotherapy with Combination of Cryotherapy and Topical Imiquimod for Treatment of Kaposi Sarcoma. Journal of Medical Virology, 95(1):e28396. PMID: 36504005.

Yang, N., Garcia, A., Meyer, Tuschl T., Merghoub, T., Wolchok, J.D., and L. Deng (2022) Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant. npj Vaccines (2022) 7(1):120. PMID: 36261460. https://doi.org/10.1038/s41541-022-00542-5.

Yang, N., Luna J.M., Dai, P., Wang, Y., Rice, C.M., and L. Deng. (2022). Lung type II alveolar epithelial cells collaborate with CCR2+ inflammatory monocytes in host defense against poxvirus infection. Nature Communications 13(1):1671. PMID: 35351885. PMCID: PMC896475.

View All Publications

People

Liang Deng, MD, PhD

Liang Deng, MD, PhD

  • Physician-scientist Liang Deng studies poxvirus interface with the immune system and the development of poxviruses as oncolytic and immunotherapy for cancers.
[email protected]
Email Address
646-888-6011
Office Phone
View physician profile
Physician profile

Members

Liang Deng, MD, PhD
Liang Deng

Lab Head

Shanza Baeer-Tariq

Research Technician

Bharath Salla

Research Technician

Yueqi Wang

Research Technician

Ning Yang
Ning Yang

Senior Research Scientist

Lab Alumni
Peihong Dai
Peihong Dai

Research Assistant

Weiyi Wang, PhD
Weiyi Wang

Senior Research Scientist

Biao Huang

Visiting Scholar

Shuaitong Liu
Shuaitong Liu

Research Technician

Gregory Mazo
Gregory Mazo

Research Fellow

Zhaoyang Niu

Research Fellow

Cristian Serna-Tamayo

Medical Student Research Fellow

Yi Wang
Yi Wang

Research Assistant

Lab Affiliations

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Liang Deng discloses the following relationships and financial interests:

  • Immunogenesis, Inc.
    Intellectual Property Rights
  • Imvaq Therapeutics
    Equity; Intellectual Property Rights; Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures